| Keywords: |
leukemia; nonhuman; conference paper; methotrexate; dna polymerase; interleukin 2; cancer immunotherapy; cell growth; chronic myeloid leukemia; angiogenesis; neovascularization, pathologic; cancer therapy; gene transfer; tumor suppressor gene; dna; leukemia cell; lymphoma; acute myeloblastic leukemia; growth regulation; gene therapy; chromosome aberrations; genetic disorder; tumor vaccine; cell adhesion; follicular lymphoma; lymphoma, follicular; hematologic disease; hairy cell leukemia; immunotoxin; prognosis; human; priority journal
|
